Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Ascletis to sell Roche’s HCV medicine danoprevir in greater China

Executive Summary

Oncology and infectious disease spec pharma Ascletis Inc. has received rights in China, Taiwan, Hong Kong, and Macau to develop, manufacture, and market Roche’s direct-acting antiviral agent danoprevir, which is in Phase II for hepatitis C virus (HCV). Ascletis will be calling the compound by the lab code ASC08.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Specialty Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • R&D and Marketing (Licensing)
    • Reverse Licensing

Related Companies